NASDAQ:NVCNNeovasc Stock Price, Forecast & News

Neovasc's stock was trading at $2.21 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVCN shares have increased by 46.2% and is now trading at $3.23. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neovasc.

Neovasc is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Neovasc.

Neovasc Inc (NASDAQ:NVCN) posted its quarterly earnings results on Thursday, May, 7th. The medical equipment provider reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.55) by $0.17. The medical equipment provider earned $0.53 million during the quarter, compared to analysts' expectations of $0.60 million. View Neovasc's earnings history.

Neovasc's stock reverse split before market open on Friday, September 21st 2018. The 1-100 reverse split was announced on Tuesday, September 11th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 20th 2018. An investor that had 100 shares of Neovasc stock prior to the reverse split would have 1 shares after the split.

3 Wall Street analysts have issued 12-month target prices for Neovasc's shares. Their forecasts range from $3.00 to $15.00. On average, they expect Neovasc's share price to reach $7.67 in the next twelve months. This suggests a possible upside of 137.4% from the stock's current price. View analysts' price targets for Neovasc.

News stories about NVCN stock have trended very negative recently, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neovasc earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutNeovasc.

Neovasc saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 244,800 shares, an increase of 18.6% from the April 30th total of 206,400 shares. Based on an average daily volume of 216,200 shares, the days-to-cover ratio is currently 1.1 days. Currently, 2.4% of the shares of the company are sold short. View Neovasc's Current Options Chain.

Some companies that are related to Neovasc include RenovaCare (RCAR), Apyx Medical (APYX), Restoration Robotics (HAIR), BeyondAirInc . (XAIR), T2 Biosystems (TTOO), Spectral Medical (EDTXF), Venus Concept (VERO), PAVmed (PAVM), SANUWAVE Health (SNWV), BRAINSWAY LTD/S (BWAY), Pro-Dex (PDEX), AIT Therapeutics (AITB), Nephros (NEPH), Nephros (NEPHD) and Sensus Healthcare (SRTS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Rexahn Pharmaceuticals (REXN), Synergy Pharmaceuticals (SGYP), Amicus Therapeutics (FOLD), Protalix Biotherapeutics (PLX), 22nd Century Group (XXII), Immune Pharmaceuticals (IMNP), Advanced Micro Devices (AMD) and Amarin (AMRN).

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

Neovasc's stock is owned by a number of institutional and retail investors. Top institutional investors include Capital World Investors (5.78%), Magnetar Financial LLC (4.28%), Morgan Stanley (0.57%) and Two Sigma Advisers LP (0.35%).

NVCN stock was sold by a variety of institutional investors in the last quarter, including Magnetar Financial LLC.

NVCN stock was acquired by a variety of institutional investors in the last quarter, including Capital World Investors, Morgan Stanley, and Two Sigma Advisers LP.

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVCN stock can currently be purchased for approximately $3.23.

Neovasc has a market capitalization of $38.15 million and generates $2.09 million in revenue each year. The medical equipment provider earns $-35,130,000.00 in net income (profit) each year or ($5.05) on an earnings per share basis. Neovasc employs 98 workers across the globe.

The official website for Neovasc is www.neovasc.com.

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The medical equipment provider can be reached via phone at 604-248-4138 or via email at [email protected]